Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma

Oncology

Volumn 72, Issue SUPPL. 1, 2007, Pages 45-51

  Miura, Norimasa ^a,g   Maruyama, Shigeo ^b   Oyama, Kenji ^b   Horie, Yutaka ^b   Kohno, Michimori ^c   Noma, Eijiro ^d   Sakaguchi, Seigo ^d   Nagashima, Miki ^e   Kudo, Masatoshi ^e   Kishimoto, Yukihiro ^f   Kawasaki, Hironaka ^f   Hasegawa, Junichi ^a   Shiota, Goshi ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Gotsu Saiseikai Hospital   (Japan)

^c Matsue Municipal Hospital   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SAN IN ROSAI HOSPITAL   (Japan)

^g TOTTORI UNIVERSITY   (Japan)

Author keywords

Cancer diagnosis; Hepatocellular carcinoma; Human telomerase reverse transcriptase protein; Real time RT PCR; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; MESSENGER RNA; NUCLEIC ACID; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

ADULT; AGED; CANCER DIAGNOSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CORRELATION ANALYSIS; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; PROTHROMBIN; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 37149034280     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111706     Document Type: Conference Paper

References (34)

1. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
2. Shirabe K, Takenaka K, Taketomi A, Kawahara N, Yamamoto K, Shimada M, et al: Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma. Cancer 1996;15:1050-1055.
3. Collier J, Sherman M: Screening of hepatocellular carcinoma. Hepatology 1998;37:273-278.
4. Dohmen K, Shirahama M, Onohama S, Miyamaoto Y, Torii Y, Irie K, et al: Differences in survival based on the type of follow-up for the detection of hepatocellular carcinoma: an analysis of 547 patients. Hepatol Res 2000;18:110-121.
5. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, Takasaki K, Nakano M: Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for 12 des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002;17:772-778.
6. Srivastava S, Gopal-Srivastava R: Biomarkers in cancer screening: a public health perspective. J Nutr 2002;132(suppl 8):2471S-2475S.
7. Srinivas PR, Kramer BS, Srivastava S: Trends in biomarker research for cancer detection. Lancet Oncol 2001;2:698-704.
8. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650.
9. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-322.
10. Anker P, Mulcahy H, Chen XQ, Stroun M: Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999;18:65-73.
11. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-1191.
12. Silva J, Silva JM, Garcia V, Garcia JM, Dominguez G, Bonilla F: RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma. Genes Chromosomes Cancer 2002;35:375-376.
13. Kopreski MS, Benko FA, Kwak LW, Gocke CD: Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 1999;5:1961-1965.
14. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P: Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000;6:3823-3826.
15. Dasi F, Lledo S, Garcia-Granero E, Ripoll R, Marugan M, Tormo M, Garcia-Conde J, Alino SF: Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest 2001;81:767-769.
16. Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, Provencio M, Espana P, Bonilla F: Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res 2001;7:2821-2825.
17. Kopreski MS, Benko FA, Gocke CD: Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann NY Acad Sci 2001;945:172-178.
18. Gal S, Fidler C, Lo YM, Chin K, Moore J, Harris AL, Wainscoat JS: Detection of mammaglobin mRNA in the plasma of breast cancer patients. Ann NY Acad Sci 2001;945:192-194.
19. Fleischhacker M, Beinert T, Ermitsch M, Seferi D, Possinger K, Engelmann C, Jandrig B: Detection of amplifiable messenger RNA in the serum of patients with lung cancer. Ann NY Acad Sci 2001;945:179-188.
20. Hasselmann DO, Rappl G, Rossler M, Ugurel S, Tilgen W, Reinhold U: Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Rep 2001;8:115-118.
21. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, Espana P, Bonilla F: Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999;59:3251-3256.
22. Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, et al: Presence of filterable and non filterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 2002;48:1212-1217.
23. Tsui NB, Ng EK, Lo YM: Stability of endogeneous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002;48:1647-1653.
24. Tatsuma T, Goto S, Kitano S, Lin YC, Lee CM, Chen CL: Telomerase activity in peripheral blood for diagnosis of hepatoma. J Gastroenterol Hepatol 2000;15:1064-1070.
25. Kopreski MS, Benko FA, Kwak LW, Gocke CD: Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 1999;5:1961-1965.
26. Chen XQ, Bonnefoi H, Pelte M-F, Lyautey J, Lederry C, Movarekhi S, et al: Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000; 6:3823-3826.
27. Miura N, Shiota G, Nakagawa T, Sano A, Marumoto A, Kishimoto Y, et al: Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology 2003;64:430-434.
28. Miura N, Horikawa I, Nishimoto A, Ohmura H, Ito H, Hirohashi S, et al: Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 1997;93:56-62.
29. Cavin LG, Romieu-Mourez R, Panta GR, Sun J, Factor VM, Thorgeirsson SS, et al: Inhibition of CK2 activity by TGF-beta 1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes. Hepatology 2003;38:1540-1551.
30. Miura N, Maeda Y, Kanbe T, Yazama H, Takeda Y, Sato R, Tsukamoto T, Sato E, Marumoto A, Harada T, Sano A, Kishimoto Y, Hirooka Y, Murawaki Y, Hasegawa J, Shiota G: Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 2005;11:3205-3209.
31. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC: High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 2004;112:44-50.
32. Takahashi S, Kitamoto M, Takaishi H, Aikata H, Kawakami Y, Nakanishi T, et al: Expression of telomerase component genes in hepatocellular carcinoma. Eur J Cancer 2000;36:496-502.
33. Waguri N, Suda T, Nomoto M, Kawai H, Mita Y, Kuroiwa T, et al: Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma;detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Cancer Res 2003;9:3004-3011.
34. Fujita Y, Fujikane T, Fujiuchi S, Nishigaki Y, Yamazaki Y, Nagase A, et al: The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 2003;98:1008-1013.